Patents by Inventor Fabienne Ricklin

Fabienne Ricklin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230331682
    Abstract: The invention relates to a compound of formula (I) Wherein A, L, R1, R2, R3 and R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 19, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
  • Publication number: 20230322776
    Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 12, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Erik Jung, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
  • Publication number: 20230145336
    Abstract: Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: December 19, 2022
    Publication date: May 11, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Katrina L. Jackson, Yanke Liang, Moses Moustakim, Morgan Welzel O'Shea, Gesine Kerstin Veits, Jeremy L. Yap, Robert T. Yu, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Bernd Kuhn, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
  • Publication number: 20230002367
    Abstract: The invention provides a bifunctional compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein said Targeting Ligand, Linker and Degron are as described herein.
    Type: Application
    Filed: October 26, 2020
    Publication date: January 5, 2023
    Inventors: Delphine GAUFRETEAU, Roman HUTTER, Eleonora JOVCHEVA, Bernd KUHN, Thomas LUEBBERS, Rainer E. MARTIN, Laetitia Janine MARTIN, Barbara Johanna MUELLER, Roger NORCROSS, Fabienne RICKLIN, Philipp SCHMID, Jean-Yves WACH, Juergen WICHMANN, Martin DUPLESSIS, Kiel LAZARSKI, Yanke LIANG
  • Publication number: 20220064178
    Abstract: The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: August 12, 2021
    Publication date: March 3, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Beat Frei, Luca Gobbi, Uwe Grether, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Didier Rombach
  • Patent number: 11117903
    Abstract: The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 14, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Beat Frei, Luca Gobbi, Uwe Grether, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Didier Rombach
  • Publication number: 20200239490
    Abstract: The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 30, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Beat Frei, Luca Gobbi, Uwe Grether, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Didier Rombach
  • Patent number: 9694012
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: July 4, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Publication number: 20170035769
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: October 24, 2016
    Publication date: February 9, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: UWE GRETHER, ATSUSHI KIMBARA, MATTHIAS NETTEKOVEN, FABIENNE RICKLIN, STEPHAN ROEVER, MARK ROGERS-EVANS, TANJA SCHULZ-GASCH
  • Patent number: 9447097
    Abstract: This invention relates to novel 4-amino-imidazoquinoline compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer or infectious diseases.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: September 20, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Hoves, Bernd Kuhn, Fabienne Ricklin, Stephan Roever
  • Patent number: 9409866
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 agonist and can be used as an active ingredient in a medicament.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: August 9, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Didier Rombach, Tanja Schulz-Gasch, Matthias Westphal
  • Publication number: 20160222010
    Abstract: This invention relates to novel 4-amino-imidazoquinoline compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer or infectious diseases.
    Type: Application
    Filed: April 7, 2016
    Publication date: August 4, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sabine Hoves, Bernd Kuhn, Fabienne Ricklin, Stephan Roever
  • Patent number: 9334268
    Abstract: This invention relates to novel 4-amino-imidazoquinoline compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer or infectious diseases.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: May 10, 2016
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Sabine Hoves, Bernd Kuhn, Fabienne Ricklin, Stephan Roever
  • Publication number: 20150344429
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 agonist and can be used as an active ingredient in a medicament.
    Type: Application
    Filed: December 4, 2013
    Publication date: December 3, 2015
    Inventors: Uwe GRETHER, Atsushi KIMBARA, Matthias NETTEKOVEN, Fabienne RICKLIN, Stephan ROEVER, Mark ROGERS-EVANS, Didier ROMBACH, Tanja SCHULZ-GASCH, Matthias WESTPHAL
  • Publication number: 20150299194
    Abstract: This invention relates to novel 4-amino-imidazoquinoline compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer or infectious diseases.
    Type: Application
    Filed: April 22, 2015
    Publication date: October 22, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Sabine Hoves, Bernd Kuhn, Fabienne Ricklin, Stephan Roever
  • Patent number: 8648099
    Abstract: The present invention relates to compounds of formula I, wherein R1 to R5 are defined in the description and claims, and to pharmaceutically acceptable salts thereof. The present invention relates also to the manufacture of said compounds, pharmaceutical compositions containing them and methods for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as dyslipidemia, atherosclerosis and cardiovascular diseases.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: February 11, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Paul Hebeisen, Peter Mohr, Fabienne Ricklin, Stephan Roever
  • Patent number: 8461160
    Abstract: This invention relates to dihydropyrimidinones of the formula wherein X and R1 to R7 are as defined in the description, as well as pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the treatment or prevention of diseases such as diabetes.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: June 11, 2013
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: David Banner, Hans Hilpert, Roland Humm, Harald Mauser, Alexander V. Mayweg, Fabienne Ricklin, Mark Rogers-Evans
  • Publication number: 20130065876
    Abstract: The present invention relates to compounds of formula I, wherein R1 to R5 are defined in the description and claims, and to pharmaceutically acceptable salts thereof. The present invention relates also to the manufacture of said compounds, pharmaceutical compositions containing them and methods for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as dyslipidemia, atherosclerosis and cardiovascular diseases.
    Type: Application
    Filed: September 11, 2012
    Publication date: March 14, 2013
    Inventors: Uwe Grether, Paul Hebeisen, Peter Mohr, Fabienne Ricklin, Stephan Roever
  • Patent number: 8227613
    Abstract: The invention is concerned with novel heteroaryl carboxamide derivatives of formula (I), wherein m, X, Y, R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: July 24, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Johannes Aebi, Alfred Binggeli, Luke Green, Guido Hartmann, Hans P. Maerki, Patrizio Mattei, Fabienne Ricklin, Olivier Roche
  • Publication number: 20120122854
    Abstract: The invention is concerned with novel carbocyclyl fused cyclic amines of formula (I) wherein A, X1 to X3, Y1 to Y3, Z, R1, R2, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Application
    Filed: January 11, 2012
    Publication date: May 17, 2012
    Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Narendra Panday, Fabienne Ricklin, Martin Stahl, Petra Schmitz